Johnson & Johnson (NYSE:JNJ) Shares Sold by Etesian Wealth Advisors Inc.

Etesian Wealth Advisors Inc. reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 18.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 5,546 shares of the company’s stock after selling 1,244 shares during the period. Etesian Wealth Advisors Inc.’s holdings in Johnson & Johnson were worth $802,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. AMF Tjanstepension AB raised its position in shares of Johnson & Johnson by 14.2% during the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock worth $68,985,000 after acquiring an additional 52,997 shares in the last quarter. Alpha Financial Partners LLC purchased a new position in Johnson & Johnson in the third quarter valued at approximately $209,000. Wealth Group Ltd. purchased a new stake in shares of Johnson & Johnson during the 3rd quarter worth approximately $213,000. Brown Miller Wealth Management LLC boosted its holdings in shares of Johnson & Johnson by 2.3% in the 3rd quarter. Brown Miller Wealth Management LLC now owns 19,673 shares of the company’s stock valued at $3,188,000 after buying an additional 436 shares in the last quarter. Finally, Mechanics Bank Trust Department grew its position in shares of Johnson & Johnson by 0.5% in the 3rd quarter. Mechanics Bank Trust Department now owns 57,568 shares of the company’s stock valued at $9,329,000 after buying an additional 272 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on JNJ shares. Barclays upped their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 28th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Morgan Stanley cut their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Royal Bank of Canada restated an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday, January 23rd. Finally, Guggenheim upped their price target on shares of Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research report on Monday, February 3rd. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Stock Down 0.3 %

JNJ opened at $153.10 on Monday. The business has a 50 day simple moving average of $147.42 and a 200-day simple moving average of $156.08. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The stock has a market capitalization of $368.61 billion, a P/E ratio of 23.02, a P/E/G ratio of 2.46 and a beta of 0.52. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business’s revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.29 EPS. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.24%. Johnson & Johnson’s payout ratio is 74.59%.

Insider Transactions at Johnson & Johnson

In other news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.